Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis

Chest

Volumn 151, Issue 3, 2017, Pages 619-625

  Morisset, Julie ^a,b   Johannson, Kerri A ^c   Vittinghoff, Eric ^a   Aravena, Carlos ^d   Elicker, Brett M ^a   Jones, Kirk D ^a   Fell, Charlene D ^c   Manganas, Helene ^b   Dubé, Bruno Pierre ^b   Wolters, Paul J ^a   Collard, Harold R ^a   Ryerson, Christopher J ^e   Ley, Brett ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

azathioprine; hypersensitivity pneumonitis; interstitial lung disease; mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; MYCOPHENOLATE MOFETIL; PREDNISONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AGE; ALLERGIC PNEUMONITIS; ARTICLE; BLOATING; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEALTH CARE FACILITY; HUMAN; HYPERTRANSAMINASEMIA; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PREDICTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEX; SMOKING; TREATMENT RESPONSE; AGED; ALVEOLITIS, EXTRINSIC ALLERGIC; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL; TREATMENT OUTCOME; VITAL CAPACITY;

AGED; ALVEOLITIS, EXTRINSIC ALLERGIC; AZATHIOPRINE; CARBON MONOXIDE; CHRONIC DISEASE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; PULMONARY DIFFUSING CAPACITY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85014519844     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.10.029     Document Type: Article

References (23)

1. 1 Selman, M., Pardo, A., King, T.E. Jr., Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 186:4 (2012), 314–324.
2. 2 Richerson, H.B., Bernstein, I.L., Fink, J.N., et al. Guidelines for the clinical evaluation of hypersensitivity pneumonitis. Report of the Subcommittee on Hypersensitivity Pneumonitis. J Allergy Clin Immunol 84:5 Pt 2 (1989), 839–844.
3. 3 Mooney, J.J., Elicker, B.M., Urbania, T.H., et al. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest 144:2 (2013), 586–592.
4. 4 Fernandez Perez, E.R., Swigris, J.J., Forssen, A.V., et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 144:5 (2013), 1644–1651.
5. 5 Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:6 (2011), 788–824.
6. 6 Morell, F., Villar, A., Montero, M.A., et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 1:9 (2013), 685–694.
7. 7 Silva, C.I., Muller, N.L., Lynch, D.A., et al. Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology 246:1 (2008), 288–297.
8. 8 Monkare, S., Influence of corticosteroid treatment on the course of farmer's lung. Eur J Respir Dis 64:4 (1983), 283–293.
9. 9 Kokkarinen, J.I., Tukiainen, H.O., Terho, E.O., Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis 145:1 (1992), 3–5.
10. 10 Kokkarinen, J.I., Tukiainen, H.O., Terho, E.O., Recovery of pulmonary function in farmer's lung. A five-year follow-up study. Am Rev Respir Dis 147:4 (1993), 793–796.
11. 11 Fischer, A., Brown, K.K., Du Bois, R.M., et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40:5 (2013), 640–646.
12. 12 Berezne, A., Ranque, B., Valeyre, D., et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35:6 (2008), 1064–1072.
13. 13 Tashkin, D.P., Roth, M.D., Clements, P.J., et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:9 (2016), 708–719.
14. 14 Bradley, B., Branley, H.M., Egan, J.J., et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63:suppl 5 (2008), v1–v58.
15. 15 Johannson, K.A., Elicker, B.M., Vittinghoff, E., et al. A diagnostic model for chronic hypersensitivity pneumonitis. Thorax 71:10 (2016), 951–954.
16. 16 Owen, C., Ngian, G.S., Elford, K., et al. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clin Exp Rheumatol 34:suppl 100[5] (2016), 170–176.
17. 17 Vourlekis, J.S., Schwarz, M.I., Cherniack, R.M., et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med 116:10 (2004), 662–668.
18. 18 Lacasse, Y., Girard, M., Cormier, Y., Recent advances in hypersensitivity pneumonitis. Chest 142:1 (2012), 208–217.
19. 19 Lota, H.K., Keir, G.J., Hansell, D.M., et al. Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax 68:8 (2013), 780–781.
20. 20 Keir, G.J., Maher, T.M., Ming, D., et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:3 (2014), 353–359.
21. 21 Allison, A.C., Eugui, E.M., Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:2-3 (2000), 85–118.
22. 22 Maltzman, J.S., Koretzky, G.A., Azathioprine: old drug, new actions. J Clin Invest 111:8 (2003), 1122–1124.
23. 23 Zheng, Y., Li, M., Zhang, Y., Shi, X., Li, L., Jin, M., The effects and mechanisms of mycophenolate mofetil on pulmonary arterial hypertension in rats. Rheumatology Int 30:3 (2010), 341–348.